- Home
- Center Of Excellence
- mCRPC Treatment
Centers of Excellence
mCRPC Treatment
From the Editor
Changes in Latitude, Changes in Attitudes…and DABGA
I write today not from the files of the Jimmy Buffet musical collection, nor from a Caribbean Margaritaville-esque cabana, as the reference might suggest (for the unfamiliar, I have been humming his song “Changes in Latitude, Changes in Attitude…for about 2 weeks now) but rather as a dispatch on the latest development in clinical trials in prostate cancer. The topic: Data from the Latitude study that was presented at ASCO by Karim Fizazi and simultaneously published in the New England Journal of Medicine.
Charles J. Ryan, MD
Charles J. Ryan, MD is Professor of Clinical Medicine and Urology and the Clinical Program Leader for Genitourinary Medical Oncology at the UCSF Helen Diller Family Comprehensive Cancer Center. He received his MD from the University of Wisconsin in Madison and completed his residency in internal medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed a fellowship in medical oncology in the Department of Medicine at Memorial Sloan-Kettering Cancer Center and the Joan and Sanford I. Weill Medical College of Cornell University in New York.
ASCO 2017 Prostate Cancer
- ASCO 2017: Challenges in Translating Molecular Results Into Meaningful Clinical Use June 5, 2017
- ASCO 2017: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer June 5, 2017
- ASCO 2017: A randomized phase II cross-over study of abiraterone + prednisone vs enzalutamide for patients with metastatic, castration-resistant prostate cancer June 3, 2017
- ASCO 2017: Targeting DNA Repair Mutations in Metastatic Castration-Resistant Prostate Cancer June 3, 2017
- ASCO 2017: Stereotactic Body Radiation: What Is Its Role in Advanced Disease? June 3, 2017
- ASCO 2017: Chemotherapy for Metastatic Castration-Resistant Prostate Cancer: Which Patient? Which Time? June 3, 2017
AUA 2016 Prostate cancer
ASCO GU 2016 Prostate Cancer
- ASCO GU 2016 More CNS Events With Enzalutamide Vs. Bicalutamide Treatment of mCRPC - Session Highlights January 18, 2016
- ASCO GU 2016 Large Study Reveals Significant Glucocorticoid Use in Both Treated and Untreated Prostate Cancer Patients - Session Highlights (Updated) January 18, 2016
ASCO GU 2016 mCRPC Treatment
- ASCO GU 2016 Among Treated Men with mCRPC, Researchers Find More Gaps in Refills with Enzalutamide Than Abiraterone - Session Highlights (Updated) January 18, 2016
- ASCO GU 2016 Clinicians’ attitudes and preferences in choosing the first line drug for mCRPC: Preliminary results from a multicenter Italian study after the introduction of abiraterone acetate (AA) January 18, 2016
- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
- CARG tool’s ability to predict older prostate cancer patients’ risk of toxicity: Beyond the Abstract
- Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer.
- Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
- A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.